OCULAR THERAPEUTIX, INC
OCUL evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $2.46B
- Lead Asset:
- dextenza (Approved)
What it means
What to watch
Prepared research question
What matters most for OCUL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCUL
Ocular Therapeutix, Inc. (OCUL) is a publicly traded biotechnology company developing sustained-release hydrogel-based therapies for retinal diseases, with a lead asset AXPAXLI in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, and a marketed product DEXTENZA.
Key risk: Single-asset dependency
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials · 1 catalyst · 1 FDA decision for OCULAR THERAPEUTIX, INC.
Similar companies
Ocular Therapeutix, Inc. (OCUL) is a publicly traded biotechnology company developing sustained-release hydrogel-based therapies for retinal diseases, with a lead asset AXPAXLI in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, and a marketed product DEXTENZA.
- Cash and equivalents of $598.6M as of 2026-06-30 [sec].
- Total revenue of $13.5M and net loss of -$78.8M for the period ending 2026-06-30 [sec].
- AXPAXLI Phase 3 SOL-1 trial in wet AMD met its primary endpoint with strong statistical significance [news · 2026-05-01].
- FDA-aligned NDA submission for AXPAXLI targeted for Q4 2026 [news · 2026-08-22].
- Raised $475M in gross proceeds in fall 2025 to support AXPAXLI development and pre-commercial activities [sec · filed 2026-04-30].
What works
- Substantial cash position of $598.6M as of 2026-06-30 provides runway into 2028 for planned operations and debt service [sec · filed 2026-04-30] [sec].
- AXPAXLI Phase 3 SOL-1 trial met its primary endpoint with strong statistical significance and a favorable safety profile, supporting an NDA path [news · 2026-05-01].
- Company has an FDA-aligned path for AXPAXLI NDA submission targeted for Q4 2026, indicating regulatory clarity [news · 2026-08-22].
- Marketed product DEXTENZA provides ongoing cash inflows to partially fund operations [sec · filed 2026-04-30].
What to weigh
- Net loss of -$78.8M for the period ending 2026-06-30, indicating ongoing operating losses [sec].
- Company is heavily reliant on a single pivotal asset, AXPAXLI, with near-term outlook tied closely to its regulatory and commercial success [news · 2026-08-22].
- Capital resources may be consumed sooner than expected if assumptions about trial costs, manufacturing scale-up, or commercial launch prove wrong [sec_mda · as of 2026-08-03].
- AXPAXLI has not yet received FDA approval, and there is no guarantee of positive outcomes from ongoing or future trials [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“cash and cash equivalents as of June 30, 2026, will enable us to fun”
SEC MD&A · August 3, 2026
AXPAXLI SOL-1 trial met primary endpoint
“SOL-1 Phase 3 trial for AXPAXLI in wet age-related macular degeneration met its primary endpoint with strong statistical significance and a favorable safety profile”
News · May 1, 2026
NDA submission target for AXPAXLI
“FDA-aligned NDA submission targeted for Q4 2026”
News · August 22, 2026
Gross proceeds raised in fall 2025
“We raised gross proceeds of $475 million to support SOL-X, the launch of our HELIOS Phase 3 program for diabetic retinal disease, and manufacturing scale-up and pre-commercial activities for AXPAXLI”
SEC filings · April 30, 2026
Catalyst timeline
- 2041-04-26 · Patent_Expiry · DEXAMETHASONE — Patent_Expiry: NDA208742 — Patent expiry for DEXTENZA (dexamethasone) could open the market to generic competition, potentially impacting future revenue from this product.
Risks & what to watch (4)›
Key risks
- Single-asset dependency — Near-term outlook is closely tied to AXPAXLI's regulatory and commercial success; failure would significantly impact the company [news · 2026-08-22].
- Operating losses — Net loss of -$78.8M as of 2026-06-30, with no guarantee of near-term profitability [sec].
- Capital consumption risk — Capital may be used sooner than expected if trial costs, manufacturing, or commercial launch assumptions prove wrong [sec_mda · as of 2026-08-03].
- Regulatory uncertainty — AXPAXLI has not yet received FDA approval; ongoing trials may fail to meet endpoints [sec_mda · as of 2026-08-03].
What to watch
- AXPAXLI NDA submission timing and FDA acceptance, targeted for Q4 2026 [news · 2026-08-22].
- Results from ongoing Phase 3 SOL and HELIOS registrational programs for AXPAXLI [sec · filed 2026-04-30].
- Cash burn rate and whether the company maintains its projected runway into 2028 [sec · filed 2026-04-30].
- DEXTENZA revenue trends and their contribution to funding operations [sec · filed 2026-04-30].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run OCULAR THERAPEUTIX, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OCULAR THERAPEUTIX, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.29 · 0% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~5308d
0 buys · 9 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
267
Total value held
$1.70B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 32,653,764 | $276.6M |
| deep track capital, lp | 19,686,282 | $166.7M |
| blackrock, inc. | 16,132,931 | $136.6M |
| avoro capital advisors llc | 12,315,000 | $104.3M |
| summer road llc | 11,879,825 | $100.6M |
| venrock adviser, llc | 10,346,926 | $87.6M |
| vanguard capital management llc | 8,719,039 | $73.9M |
| alliancebernstein l.p. | 4,129,687 | $50.1M |
| point72 asset management, l.p. | 5,534,985 | $46.9M |
| state street corp | 4,708,419 | $39.9M |
Showing top 10 of 267 institutional holders of OCULAR THERAPEUTIX, INC. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 13.4%
- Days to cover
- 7.5
- Shares short
- 24,793,045
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCUL short interestGovernance
Frequently asked questions
What is the AI investment thesis for OCULAR THERAPEUTIX, INC?
Ocular Therapeutix, Inc. (OCUL) is a publicly traded biotechnology company developing sustained-release hydrogel-based therapies for retinal diseases, with a lead asset AXPAXLI in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, and a marketed product DEXTENZA.
What is OCULAR THERAPEUTIX, INC's lead drug candidate?
OCULAR THERAPEUTIX, INC's most advanced tracked candidate is dextenza (Approved) for Cataract.
What is OCULAR THERAPEUTIX, INC's next catalyst?
OCULAR THERAPEUTIX, INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA208742" — expected April 26, 2041.
Who is the CEO of OCULAR THERAPEUTIX, INC?
Dr. Pravin U. Dugel M.D. is the chief executive officer of OCULAR THERAPEUTIX, INC (OCUL).
Where is OCULAR THERAPEUTIX, INC headquartered?
OCULAR THERAPEUTIX, INC (OCUL) is headquartered in Bedford, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.